Intermittent topical treatment of psoriasis with clobetasol propionate ("Dermovate").
In an open multi-centre trial, 316 psoriasis patients were treated with clobetasol propionate intermittently over a 14-day period. The treatment gave rapid clinical healing of the psoriasis infiltration in 62% of the patients. A total of 132 of these patients was subsequently put on maintenance treatment with two applications per week. This regimen kept the disease in remission throughout the observation period, which exceeded 4 months on average, in 75% of the patients. Only 5 patients experienced side-effects.
D000287:Administration, Topical; D001623:Betamethasone / Q000031:analogs & derivatives*; D002986:Clinical Trials as Topic; D002990:Clobetasol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*
D001623:Betamethasone; D002990:Clobetasol